Compare · GILD vs RXRX
GILD vs RXRX
Side-by-side comparison of Gilead Sciences Inc. (GILD) and Recursion Pharmaceuticals Inc. (RXRX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GILD and RXRX operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- GILD is the larger of the two at $161.19B, about 85.4x RXRX ($1.89B).
- Over the past year, GILD is up 16.1% and RXRX is down 34.8% - GILD leads by 50.9 points.
- RXRX has been more active in the news (11 items in the past 4 weeks vs 5 for GILD).
- GILD has more recent analyst coverage (25 ratings vs 10 for RXRX).
- Company
- Gilead Sciences Inc.
- Recursion Pharmaceuticals Inc.
- Price
- $130.15+0.26%
- $3.44-3.64%
- Market cap
- $161.19B
- $1.89B
- 1M return
- +7.16%
- +13.34%
- 1Y return
- +16.05%
- -34.85%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1992
- 2021
- News (4w)
- 5
- 11
- Recent ratings
- 25
- 10
Gilead Sciences Inc.
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.
Recursion Pharmaceuticals Inc.
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. It has four clinical-stage drug candidates focused on rare, monogenic diseases; and 33 additional programs in various stages of preclinical development. Recursion Pharmaceuticals, Inc. has strategic agreements with Bayer; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. The company was founded in 2013 and is based in Salt Lake City, Utah.
Latest GILD
- Gilead Sciences upgraded by HSBC Securities with a new price target
- Chairman & CEO O'Day Daniel Patrick sold $1,894,400 worth of shares (15,000 units at $126.29) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 607,133 units (SEC Form 4)
- U.S. FDA Approves Trodelvy® for First-Line Treatment of Metastatic Triple-Negative Breast Cancer
- Next-Generation DNA Repair Inhibitors Could Capture Billions in Emerging Market
- European Commission Approves Trodelvy® as a First-Line Treatment for Metastatic Triple-Negative Breast Cancer Patients Not Candidates for PD-(l)1 Inhibitors
- Chief Comm & Corp Aff Officer Mercier Johanna sold $371,762 worth of shares (3,000 units at $123.92) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 124,234 units (SEC Form 4)
- Chief Financial Officer Dickinson Andrew D sold $376,200 worth of shares (3,000 units at $125.40) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 171,646 units (SEC Form 4)
- U.S. FDA Accepts Gilead's Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First Long-Acting Pill for HIV Prevention
- Gilead Mobilizes Rapid Donation of Remdesivir to Support Ebola Response, Building on Decade-Long Commitment to Outbreak Relief
- Chief Medical Officer Berger Dietmar covered exercise/tax liability with 263 shares and converted options into 533 shares, increasing direct ownership by 1% to 19,252 units (SEC Form 4)
Latest RXRX
- Director Borgeson Blake sold $158,500 worth of shares (40,000 units at $3.96) as part of a pre-agreed trading plan, decreasing direct ownership by 0.64% to 6,218,287 units (SEC Form 4)
- Director Dar Zavain was granted 5,109 shares, increasing direct ownership by 2% to 240,764 units (SEC Form 4)
- Director Li Dean Y was granted 3,747 shares, increasing direct ownership by 0.25% to 1,473,329 units (SEC Form 4)
- A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs
- Director Borgeson Blake was granted 88,424 shares, increasing direct ownership by 1% to 6,258,287 units (SEC Form 4)
- Director Hershberg Robert was granted 88,424 shares, increasing direct ownership by 120% to 162,156 units (SEC Form 4)
- Director Michor Franziska was granted 88,424 shares, increasing direct ownership by 70% to 215,477 units (SEC Form 4)
- Director Sun Elaine D was granted 88,424 shares, increasing direct ownership by 186% to 135,981 units (SEC Form 4)
- Director Dar Zavain was granted 88,424 shares, increasing direct ownership by 60% to 235,655 units (SEC Form 4)
- Director Bumpus Namandje was granted 88,424 shares and sold $12,602 worth of shares (3,963 units at $3.18) as part of a pre-agreed trading plan, increasing direct ownership by 196% to 127,632 units (SEC Form 4)